An AI that measures lung scarring can only help if a patient understands what the measurement means. Brainomix and the Pulmonary Fibrosis Foundation are pairing up to find out.
Testing whether quantitative scans aid conversation
The multi-phase initiative will examine how patients and caregivers respond when Brainomix 360 e-Lung, an FDA-cleared and CE-marked tool, supplies quantitative CT metrics alongside a clinician’s read. Brainomix 360 e-Lung automatically quantifies and visualizes radiographic features in lung CT scans to support diagnostic assessment of lung disease.
The research will probe what patients want to know about their disease, how they interpret visual and numerical outputs, and whether those outputs make decisions about starting, continuing or switching treatment easier. That matters most when symptoms have not yet shifted but imaging has.
Built on a Boehringer Ingelheim study
The partnership sits inside PROGRESS-PPF, a broader program between Brainomix and Boehringer Ingelheim probing whether quantitative CT can give clinicians objective signals of disease progression in progressive pulmonary fibrosis.
The foundation will draw on its patient community and its Care Center Network, which links medical centers with fibrotic lung disease expertise. Chief executive Scott Staszak framed the work as bringing patients into the evaluation of the technology.
Brainomix chief executive Michalis Papadakis said the company needs to learn how imaging tools communicate to the people living with the disease.
For AI vendors selling into pulmonology, the study touches a recurring gap: clearance proves accuracy, not comprehension.
